ACUTE MYELOID LEUKEMIA CARRYING CYTOPLASMIC / MUTATED NUCLEOPHOSMIN ( NPMc + AML ) : BIOLOGICAL AND CLINICAL FEATURES

word count: 200; Total word count: 4990. Supported by the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.). Reprints: Brunangelo Falini, Institute of Hematology, Policlinico, Monteluce, 06122 Perugia, Italy. Tel. +39-075-5783190; Fax:+39-075-5783834; E-mail: faliniem@unipg.it or Cristina Mecucci, Institute of Hematology, Policlinico, Monteluce, 06122 Perugia, Italy, E-mail: crimecux@unipg.it Blood First Edition Paper, prepublished online October 2, 2006; DOI 10.1182/blood-2006-07-012252 Copyright © 2006 American Society of Hematology For personal use only. on April 3, 2017. by guest www.bloodjournal.org From

[1]  M. Olson,et al.  Nucleolar protein B23 has molecular chaperone activities , 2008, Protein science : a publication of the Protein Society.

[2]  R. Arceci.  Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification , 2007 .

[3]  C. Bloomfield,et al.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? , 2007, Blood.

[4]  Myriam Alcalay,et al.  Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. , 2006, Blood.

[5]  M. Olson,et al.  Effects of interphase and mitotic phosphorylation on the mobility and location of nucleolar protein B23 , 2006, Journal of Cell Science.

[6]  C. Sherr.  Divorcing ARF and p53: an unsettled case , 2006, Nature Reviews Cancer.

[7]  Jiang Li,et al.  High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). , 2006, Blood.

[8]  P. Pelicci,et al.  Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal , 2006, Oncogene.

[9]  Pier Paolo Pandolfi,et al.  Nucleophosmin and cancer , 2006, Nature Reviews Cancer.

[10]  N. Bolli,et al.  Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML , 2006, Leukemia.

[11]  O. Bernard,et al.  Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype , 2006, Leukemia.

[12]  June Li,et al.  Nucleophosmin Regulates Cell Cycle Progression and Stress Response in Hematopoietic Stem/Progenitor Cells* , 2006, Journal of Biological Chemistry.

[13]  W. Hiddemann,et al.  Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. , 2006, Blood.

[14]  D. Steensma,et al.  C‐terminal nucleophosmin mutations are uncommon in chronic myeloid disorders , 2006, British journal of haematology.

[15]  B. Falini,et al.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.

[16]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[17]  M. Dai,et al.  Nucleophosmin Is Essential for Ribosomal Protein L5 Nuclear Export , 2006, Molecular and Cellular Biology.

[18]  B. Falini,et al.  Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. , 2006, The Journal of molecular diagnostics : JMD.

[19]  N. Bolli,et al.  Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. , 2006, The Lancet. Oncology.

[20]  R. Gjerset,et al.  Regulation of p14ARF Through Subnuclear Compartmentalization , 2006, Cell cycle.

[21]  M. Yao,et al.  Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. , 2006, Cancer research.

[22]  P. Pelicci,et al.  Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. , 2006, Cancer research.

[23]  Hitoshi Suzuki,et al.  Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre‐mRNA processing , 2006, FEBS letters.

[24]  Xiaoling Zhang,et al.  Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells. , 2005, Leukemia research.

[25]  Bob Löwenberg,et al.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.

[26]  R. Gallagher.  Dueling mutations in normal karyotype AML , 2005 .

[27]  J. Downing,et al.  Pediatric Acute Myeloid Leukemia with Nucleophosmin Mutations Is Characterized by a Gene Expression Signature with Dysregulated HOX Gene Expression Distinct from MLL-Rearranged Leukemias. , 2005 .

[28]  J. Cayuela,et al.  Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.

[29]  F. Lo‐Coco,et al.  Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC. , 2005, Clinical chemistry.

[30]  Brian A. Smith,et al.  DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. , 2005, Cancer research.

[31]  T. Naoe,et al.  Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. , 2005, Blood.

[32]  B. Falini,et al.  Nucleophosmin Is Required for DNA Integrity and p19Arf Protein Stability , 2005, Molecular and Cellular Biology.

[33]  N. Bolli,et al.  Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin , 2005, Leukemia.

[34]  P. Pandolfi,et al.  Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.

[35]  A. Budhu,et al.  Loading and Unloading: Orchestrating Centrosome Duplication and Spindle Assembly by Ran/Crm1 , 2005, Cell cycle.

[36]  C. Sherr,et al.  Myeloid Leukemia-Associated Nucleophosmin Mutants Perturb p53-Dependent and Independent Activities of the Arf Tumor Suppressor Protein , 2005, Cell cycle.

[37]  B. Falini,et al.  Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. , 2005, Blood.

[38]  B. Falini,et al.  Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia , 2005, Leukemia.

[39]  Natalia Meani,et al.  Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.

[40]  X. Wang,et al.  Temporal and spatial control of nucleophosmin by the Ran–Crm1 complex in centrosome duplication , 2005, Nature Cell Biology.

[41]  Jun Qin,et al.  ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor , 2005, Cell.

[42]  Chunaram Choudhary,et al.  AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. , 2005, Blood.

[43]  K. Ye.  Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis , 2005, Cancer biology & therapy.

[44]  Y. Yun,et al.  A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin-binding proteins in response to DNA double-strand breaks. , 2005, The Biochemical journal.

[45]  R. Suzuki,et al.  Nucleophosmin in acute myelogenous leukemia. , 2005, The New England journal of medicine.

[46]  Lina A. Thoren,et al.  Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential A Revised Road Map for Adult Blood Lineage Commitment , 2005, Cell.

[47]  Zhihua Liu,et al.  B23 Regulates GADD45a Nuclear Translocation and Contributes to GADD45a-induced Cell Cycle G2-M Arrest* , 2005, Journal of Biological Chemistry.

[48]  Ulrike Kutay,et al.  Leucine-rich nuclear-export signals: born to be weak. , 2005, Trends in cell biology.

[49]  C. Preudhomme,et al.  CEBPA point mutations in hematological malignancies , 2005, Leukemia.

[50]  C. Korgaonkar,et al.  Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function , 2005, Molecular and Cellular Biology.

[51]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[52]  Anthony K. L. Leung,et al.  Nucleolar proteome dynamics , 2005, Nature.

[53]  Guido Marcucci,et al.  Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics , 2005, Current opinion in hematology.

[54]  C. Akey,et al.  The structure and function of Xenopus NO38-core, a histone chaperone in the nucleolus. , 2004, Structure.

[55]  J. Weber,et al.  ARF Impedes NPM/B23 Shuttling in an Mdm2-Sensitive Tumor Suppressor Pathway , 2004, Molecular and Cellular Biology.

[56]  U. Vinkemeier,et al.  Ratjadone and leptomycin B block CRM1‐dependent nuclear export by identical mechanisms , 2004, FEBS letters.

[57]  Xia Ding,et al.  Nek2A kinase regulates the localization of numatrin to centrosome in mitosis , 2004, FEBS letters.

[58]  M. Fornerod,et al.  Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358 , 2004, The EMBO journal.

[59]  W. Dai,et al.  B23/Nucleophosmin Serine 4 Phosphorylation Mediates Mitotic Functions of Polo-like Kinase 1* , 2004, Journal of Biological Chemistry.

[60]  Mei-Ling Kuo,et al.  N-terminal polyubiquitination and degradation of the Arf tumor suppressor. , 2004, Genes & development.

[61]  S. Kurki,et al.  Nucleophosmin, HDM2 and p53: Players in UV Damage Incited Nucleolar Stress Response , 2004, Cell cycle.

[62]  F. Carrier,et al.  Nucleophosmin Sets a Threshold for p53 Response to UV Radiation , 2004, Molecular and Cellular Biology.

[63]  Leena Latonen,et al.  Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. , 2004, Cancer cell.

[64]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[65]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[66]  Yanping Zhang.  The ARF-B23 Connection: Implications for Growth Control and Cancer Treatment , 2004, Cell cycle.

[67]  S. Fröhling,et al.  CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Pamela A. Silver,et al.  Nuclear transport and cancer: from mechanism to intervention , 2004, Nature Reviews Cancer.

[69]  Charles J. Sherr,et al.  Physical and Functional Interactions of the Arf Tumor Suppressor Protein with Nucleophosmin/B23 , 2004, Molecular and Cellular Biology.

[70]  J. Yun,et al.  Nucleophosmin/B23 is a proliferate shuttle protein associated with nuclear matrix , 2003, Journal of cellular biochemistry.

[71]  J. Milner,et al.  Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses , 2003, The EMBO journal.

[72]  David Hawke,et al.  Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. , 2003, Molecular cell.

[73]  H. Dombret,et al.  Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.

[74]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[75]  G. Ehninger,et al.  Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia , 2003, Genes, chromosomes & cancer.

[76]  J. Milner,et al.  p53: Guardian of a Genome's Guardian? , 2003, Cell cycle.

[77]  M. Okuda.  The role of nucleophosmin in centrosome duplication , 2002, Oncogene.

[78]  Florence Dalenc,et al.  Increased expression of a COOH‐truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells , 2002, International journal of cancer.

[79]  S. Fröhling,et al.  Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[81]  Pier Giuseppe Pelicci,et al.  Nucleophosmin regulates the stability and transcriptional activity of p53 , 2002, Nature Cell Biology.

[82]  H. Dombret,et al.  A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. , 2002, Blood.

[83]  B. Falini,et al.  Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. , 2002, Blood.

[84]  H. Umekawa,et al.  Tryptophans 286 and 288 in the C-terminal Region of Protein B23.1 are Important for Its Nucleolar Localization , 2002, Bioscience, biotechnology, and biochemistry.

[85]  K. Nagata,et al.  Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone , 2001, FEBS letters.

[86]  H. F. Horn,et al.  Specific Phosphorylation of Nucleophosmin on Thr199 by Cyclin- dependent Kinase 2-Cyclin E and Its Role in Centrosome Duplication* , 2001, The Journal of Biological Chemistry.

[87]  H. F. Horn,et al.  Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication , 2000, Cell.

[88]  M. Olson,et al.  Mapping the Functional Domains of Nucleolar Protein B23* , 2000, The Journal of Biological Chemistry.

[89]  W. Hiddemann,et al.  Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML , 2000, Leukemia.

[90]  B. Henderson,et al.  A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. , 2000, Experimental cell research.

[91]  E. Campo,et al.  Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. , 1999, Blood.

[92]  P. Chan,et al.  A study of correlation between NPM-translocation and apoptosis in cells induced by daunomycin. , 1999, Biochemical pharmacology.

[93]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[94]  B Falini,et al.  Detection of normal and chimeric nucleophosmin in human cells. , 1999, Blood.

[95]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[96]  R. Savkur,et al.  Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease. , 1998, Nucleic acids research.

[97]  Minoru Yoshida,et al.  CRM1 is responsible for intracellular transport mediated by the nuclear export signal , 1997, Nature.

[98]  K. Pulford,et al.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis , 1997, Molecular and cellular biology.

[99]  B. Cullen,et al.  Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay , 1996, Molecular and cellular biology.

[100]  A. Nordgren,et al.  Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology. , 1996, Leukemia.

[101]  S. Corey,et al.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. , 1996, Blood.

[102]  S. Raimondi,et al.  The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. , 1996, Oncogene.

[103]  J. Herrera,et al.  The ribonuclease activity of nucleolar protein B23. , 1995, Nucleic acids research.

[104]  P. Chan,et al.  Nucleophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells. , 1995, Biochimica et biophysica acta.

[105]  M. Olson,et al.  The nucleic acid binding activity of nucleolar protein B23.1 resides in its carboxyl-terminal end. , 1994, The Journal of biological chemistry.

[106]  R. Berger,et al.  P53 gene mutations in acute myeloid leukemia with 17p monosomy. , 1991, Blood.

[107]  J. Chang,et al.  Structure of the gene for rat nucleolar protein B23. , 1990, The Journal of biological chemistry.

[108]  C. Lehner,et al.  Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.

[109]  N. Feuerstein,et al.  Identification of numatrin, the nuclear matrix protein associated with induction of mitogenesis, as the nucleolar protein B23. Implication for the role of the nucleolus in early transduction of mitogenic signals. , 1988, The Journal of biological chemistry.

[110]  B. Yung,et al.  Identification and characterization of a hexameric form of nucleolar phosphoprotein B23. , 1987, Biochimica et biophysica acta.

[111]  K. Sikora,et al.  Leukemia , 1984, British Journal of Cancer.

[112]  H. Tien,et al.  A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias , 2007, Leukemia.

[113]  Yue Zhang,et al.  NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. , 2007, Leukemia research.

[114]  R. Kefford,et al.  The ARF tumour suppressor. , 2006, The international journal of biochemistry & cell biology.

[115]  J. Issa,et al.  Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. , 2006, Haematologica.

[116]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype , 2005 .

[117]  S. Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[118]  R. Ochs,et al.  Silver staining, immunofluorescence, and immunoelectron microscopic localization of nucleolar phosphoproteins B23 and C23 , 2004, Chromosoma.

[119]  C. Felix,et al.  The molecular basis of leukemia. , 2004, Hematology. American Society of Hematology. Education Program.

[120]  C. Preudhomme,et al.  New mechanisms of AML1 gene alteration in hematological malignancies , 2003, Leukemia.

[121]  Søren Brunak,et al.  NESbase version 1.0: a database of nuclear export signals , 2003, Nucleic Acids Res..

[122]  Articles on similar topics can be found in the following Blood collections , 2002 .

[123]  G. Behre,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. , 2001, Nature genetics.

[124]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.

[125]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[126]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.

[127]  H. Umekawa,et al.  Expression and subcellular locations of two forms of nucleolar protein B23 in rat tissues and cells. , 1993, Cellular & molecular biology research.

[128]  B. Seshachar,et al.  The nucleolus. , 1946, Current science.

[129]  G. Ehninger,et al.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. , 2002, Blood.